Vertex Pharmaceuticals (VRTX) Capital Expenditures (2009 - 2026)

Vertex Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 227.76% year-over-year to $133.4 million in Q1 2026; TTM through Mar 2026 was $530.3 million, a 96.41% increase from a year earlier, with the FY2025 full-year figure at $437.6 million, up 46.99% from the prior year.
• Capital Expenditures declined to $133.4 million in Q1 2026 per VRTX's latest filing, from $149.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $149.4 million in Q4 2025 and bottomed at $33.6 million in Q4 2022.
• The 5-year median for Capital Expenditures is $63.6 million (2022), against an average of $74.9 million.
• Across the five-year window, Capital Expenditures slumped 45.63% in 2022 and surged 227.76% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $33.6 million in 2022, then jumped by 72.92% to $58.1 million in 2023, then surged by 59.38% to $92.6 million in 2024, then surged by 61.34% to $149.4 million in 2025, then decreased by 10.71% to $133.4 million in 2026.
• Per Business Quant, the three latest VRTX Capital Expenditures figures stand at $133.4 million (Q1 2026), $149.4 million (Q4 2025), and $101.8 million (Q3 2025).